Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tepezza (teprotumumab-trbw) binds to insulin-like growth factor-1 receptor (IGF-1R) and blocks its activation and signaling. It is being investigated in patients with thyroid eye disease.
Product Name : Tepezza
Product Type : Antibody
Upfront Cash : Inapplicable
October 04, 2023
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tepezza, (teprotumumab-trbw) first medicine approved by FDA for treatment of TED, among thousands of patients included in this 19-month new post-marketing Safety analysis, approximately 10% of all cases reported to safety database have included a hearing...
Product Name : Tepezza
Product Type : Antibody
Upfront Cash : Inapplicable
February 15, 2022
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable